Cyrpa

Una marca de calidad e innovación en el sector médico

TelTechnical Hotline : support@c-rad.com

Follow us LinkedIn Twitter

NewsBack to the news


04 12 2015 China approves Cyrpa’s laser positioning products for use in radiation therapy

04 12 2015 China approves Cyrpa’s laser positioning products for use in radiation therapy

The China Food and Drug Administration has approved the sale of C-RAD’s Cyrpa laser systems on the Chinese market.

 

These systems are already installed in all three sales regions – Asia, North America and Europe – and after making a strong presence at medical trade fairs, China has now given the green light for filling orders that were waiting for CFDA registration to fall into place. The product line has already been cleared for sales in Europe and the USA as well as several other markets in Asia.

The Cyrpa laser products support virtual simulation in a multi-modality imaging environment such as CT, MR and PET-CT but also patient positioning in photon, proton and heavy ion treatment rooms.

C-RAD and Cyrpa are working in China with direct sales and a distributor, Beijing HGPT Technology & Trade Co. The efforts have resulted in an order backlog that was pending the granting of registration. An order worth approximately SEK 2 million was received from the Chinese distributor after the license was granted.

The total market for laser systems with advanced imaging in China is around 100 systems a year, and C-RAD is aiming to achieve a 30% market share in 2017.

 “After demonstrating our products in China, it’s an enormous boost to obtain the CFDA certification,” says Tim Thurn, C-RAD’s CEO. “Our good cooperation with our distributor has led to opening up the full potential of the Chinese market, putting us in a position for rapid growth. It also allows us to further exploit our Cyrpa strategy, since the synergies from offering a complete portfolio strengthen our position in customer negotiations.”

“It's a great success to receive the CFDA certification, we are proud to advance in penetration of foreign markets, specially China, that has a huge potential for high quality laser patient positioning systems like Cyrpa's, ” says Rocio Hernandez Viciana, Cyrpa’s Vice President.

Cyrpa’s HIT (High Impact Technology) laser systems are used for patient positioning during virtual simulation and radiotherapy treatment. HIT systems include two major innovations: double-diode for each laser line, and the SmartPhantom, which allows high precision automatic calibration of the laser system in the CT room. Cyrpa is the only positioning laser manufacturer that guarantees an accuracy of 0.1mm.

In July 2015 Cyrpa became a wholly owned subsidiary of C-RAD AB.